Integrating Effective Referral and Care Coordination Processes for CAR T-Cell Therapy for Treatment of DLBCL and FL

Learning Objectives:Upon completion of this activity, participants should be better able to: Assess current practice patterns to identify facilitators and barriers to the timely referral of patients eligible for chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) Describe the roles of community oncologists and CAR T-cell specialists in referring and managing patients eligible for or receiving CAR T-cell therapy by identifying optimal workflows that have been established by leading CAR T-cell specialty centers and surrounding community-based clinics Employ interprofessional team-based strategies to improve referral, treatment, communication, and care coordination between oncology clinics and CAR T-cell centers to optimize outcomes for patients with DLBCL/FL assess current practice patterns to identify facilitators and barriers to the timely referral of patients eligible for chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)

Learning Objectives:Upon completion of this activity, participants should be better able to: Assess current practice patterns to identify facilitators and barriers to the timely referral of patients eligible for chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) Describe the roles of community oncologists and CAR T-cell specialists in referring and managing patients eligible for or receiving CAR T-cell therapy by identifying optimal workflows that have been established by leading CAR T-cell specialty centers and surrounding community-based clinics Employ interprofessional team-based strategies to improve referral, treatment, communication, and care coordination between oncology clinics and CAR T-cell centers to optimize outcomes for patients with DLBCL/FL describe the roles of community oncologists and CAR T-cell specialists in referring and managing patients eligible for or receiving CAR T-cell therapy by identifying optimal workflows that have been established by leading CAR T-cell specialty centers and surrounding community-based clinics

Learning Objectives:Upon completion of this activity, participants should be better able to: Assess current practice patterns to identify facilitators and barriers to the timely referral of patients eligible for chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) Describe the roles of community oncologists and CAR T-cell specialists in referring and managing patients eligible for or receiving CAR T-cell therapy by identifying optimal workflows that have been established by leading CAR T-cell specialty centers and surrounding community-based clinics Employ interprofessional team-based strategies to improve referral, treatment, communication, and care coordination between oncology clinics and CAR T-cell centers to optimize outcomes for patients with DLBCL/FL employ interprofessional team-based strategies to improve referral, treatment, communication, and care coordination between oncology clinics and CAR T-cell centers to optimize outcomes for patients with DLBCL/FL